Focusing on clinical trials involving DEBIO 1143, Dipersio et al. revealed that responders more frequently showed plasma increases of TNF-α and IL-8 post-first dose of DEBIO 1143 during AML treatment (when patients were treated with a combination of DEBIO 1143, daunorubicin, and cytarabine)48. Here, TNF is linked to acute myeloid leukemia.